Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA

NCT06323148 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06323148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06323148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA
Lead sponsor
Fudan University
Phase
Phase 3
Overall status
Not yet recruiting
Start date
April 1, 2024
Completion date
March 31, 2029
Enrollment
226 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

egfr gene mutation, lung cancer, minimal residual disease